DEERFIELD, ILL. — RTI Surgical Holdings Inc., a global surgical implant company, recently announced it had completed the acquisition of Paradigm Spine, LLC, a leader in motion preservation and non-fusion spinal implant technology.

“The acquisition of Paradigm aligns with RTI’s growth strategy focused on investing in differentiated products and building scale within our spine business,” Camille Farhat, president and CEO of RTI Surgical, said in a news release. “It marks the second completed acquisition for RTI’s spine portfolio since the second half of 2017 when we initiated a strategic transformation to reduce complexity, drive operational excellence and accelerate growth for RTI.”

Coflex, Paradigm’s main product, is a differentiated, minimally invasive motion preserving stabilization implant that is FDA PMA-approved for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression. LSS is a debilitating and degenerative disease that impacts approximately 1.6 million patients annually in the United States. Coflex is a significant addition to RTI’s existing spine portfolio, which consists of high-quality hardware, interbody and biologic options.